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Sommaire
L’objectif de cette étude est d’évaluer l’effet de la charge en médicament et du
niveau d’agent plastifiant sur la cinétique de libération à partir d’un film
polymérique d’acide polylactique (PLA). Premièrement, des films polymériques
d’acide polylactique composé de 50 ¾ basse (Mw 64800) et de 50% haute (Mw
252000) masse moléculaire avec différentes charges en médicament (20, 25 et
30%) ont été préparé sans agent plastifiant dibutyl sebacate (DBS) afin d’évaluer
la libération de pentoxifylline des matrices polymériques. Deuxièmement, l’agent
plastifiant (DBS) à différents niveaux (10, 20 et 30%) a été ajouté à la formulation
afin d’évaluer la libération de pentoxifylline des matrices polymériques. Le
Differential Scanning Calorimetry (DSC) (Mettler TC Il TA processor) a été
employé pour caractériser et étudier le comportement thermique des films et du
médicament. Le GPC (Gel Permeation Chromatography) (model ALC-202 liquid
chromatographs Waters associates lnc) a été employé pour caractériser le poids
moléculaire des échantillons d’acide polylactique. Le Scanning Electron
Microscopy (SEM, Jeol Inc. Peabody.MA JSM-5900LV) a été employé pour
caractériser la surface des films à différentes charges de médicament. La
diffraction au rayon X (Scintag XDS-2000, Si (Li) Peltier-cooled solid state
detector) a été utilisée (source de CuKaipha à une puissance de générateur de
45 kilovolts et d’ampérage de 40 mA) pour détecter les pics du médicament à
l’état cristallin et de l’acide polylactique. On a observé un effet significatif des
niveaux de chargement de drogue sur le taux de libération du médicament.
L’effet de l’agent plastifiant sur le taux de libération du médicament dépend des
niveaux de charge. À basse charge (70 et 20%), à mesure que le niveau de
plastifiant augmente le taux de libération augmente, alors qu’à charge élevée
(60%) le taux de libération diminue.
Mot-Clé : Acide polylactique, Charges en médicament, Plastifiant, Libération du
médicament.
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Summary
The objective of this study was to evaluate the effect ot drug loading
and plasticizer level on the release kinetic f rom films composed of
polylactic acïd (PLA). First, the polymeric film of polylactic acid of 50 % low
and 50% high molecular weights with different drug loadings (20, 25 and
30%) was prepared without the plasticizer (DES) to evaluate the drug
(pentoxifylline) release f rom the polymeric matrix. Secondly, the plasticizer
(DES) with different levels (10, 20 and 30 ¾) was added to the formulation
and the drug release f rom the polymeric film was evaluated. Differential
Scanning Calorimetry (Mettler 10 II TA processor) was used to
characterize and study thermal behavior of the film and the drug. Gel
Permeation Chromatography GPC (model ALC-202 liquid chromatographs
Waters associates mc) was used to characterize the molecular weight of
the polylactic acid. Scanning Electron Microscopy, (Jeol Inc. Peabody.MA
JSM-5900LV) was used to characterize the film surface at different drug
Ioadings. X-ray powder diffraction using Scintag XDS-2000, Si (Li) Peltier
cooled solid state detector (CuKalpha source at a generator power of 45
kV and amperage cf 40 mA) was used to measure crystals peaks ot the
drug and the polylactic acid. The study was done to evaluate the effect of
the drug loading levels and plasticizer levels on the drug release rate f rom
the polymeric film. A significant effect of the drug loading levels on the
drug release rate was observed. The effect of plasticizer on the drug
11
release rate has a different effect based on the drug loading levels, at 10w
drug loading level (10 and 20%), as plasticizer level increases the drug
release rate , while at high drug loading (60% ) the drug release rate
decreases as the plasticizer level increases.
Key Words: polylactic acid, drug loading, plasticizer, drug release.
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I. Theoretïcal
A. Introduction
A number of factors have prompted the recent focus in pharmaceutical
research on the development of new drug delivery systems. First, the
extension of patent protection for existing drugs coming off patent is weli
suited to the concepts and techniques of controlled release drug delivery
systems. Second, new drug delivery systems are often the only conceivable
approach to delivering genetically engineered pharmaceuticals such as
peptides and proteins to their site of action without causing significant
immunogenicity or biological inactivation. Third, targeting specific sites of
action improves the treatment of enzyme-deficient diseases and cancer.
Finaily, reducing the size and number of doses helps prevent the side effects
arising f rom conventional methods.[1J
While the search for new drugs remains the prime objective of
pharmaceutical research, recent decades have marked a shift in the focus of
pharmaceutical research to the conception and creation of new drug delivery
systems. Different methods are used to prolong drug action, drug availability,
and duration of effect. Combining drugs with substances that decrease their
solubility, coating drugs with materials that do flot dissolve in the stomach
acid or that are either insoluble or slowly soluble, compressing drugs in
dense tablets, or putting drugs into suspension or emulsion are ail
techniques to improve drug efficacy and bioavailability. [2, 3]
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1. Drug delïvery systems
a) Defïnition and introduction
An ideal drug delivery system can be achieved through one of two
mechanisms. First, the drug should be delivered at a rate dictated by the
needs ot the body over the period of treatment. A clear relationship between
steady state plasma levels and the resultant therapeutic response requires a
constant rate for drug delivery. Second, the drug should be delivered to
;specific receptors, such as H1 and H2 antagonists’ to specific targets, such
as tumor ceils; or to a specific area of the body, such as the joints for the
treatment of arthritis or goutjl]
Controlled release drug delivery systems can deliver a drug, either
systemically or locally, at a predetermined rate for a specific period; however,
such systems have no control over the fate of the drug once it enters the
body. Even though targeted drug delivery systems can achieve site-specific
delivery, they are as of yet incapable of controlling the release kinetics of
drugs in a predicable manner.[1, 4]
I Conventional release
fa) Definition
Most active agents are administered orally, according to a specific
administration schedule for immediate release into and rapid absorption by
the circulation system. The drug/blood levels necessary for obtaining a
therapeutic response require an initially high release rate. The drug
concentration in the blood decreases over time; therefore, turther doses must
be administered at specific time intervals to maintain a therapeutic level of
the drug. These conventional drug administration techniques (intravenous
injection and oral tablets) normally provide poor control of plasma drug
concentrations, thus requiring large amounts of drug to maintain therapeutic
levels. This renders such delivery systems costly and inefficient.[4-6J
(b) Advantages
Despite certain limitations, conventional dosage forms can yield the
desired therapeutic levels using proper dose and dosing intervalsj6]
(c) Disadvantages
Because of the wide distribution in blood levels, conventional dosage
forms are flot suitable for the oral administration of drugs that have narrow
therapeutic ranges. The treatment success of these classic drug delivery
systems is highly dependent on patient compliance. Drugs with short haif
lives will produce large valley and peak blood level profiles, thus rendering
them unsuitable for the treatment of some diseases. For glaucoma, for
example, Ocusert® Pilocarpine is used to decrease intraocular pressure,
rather than a conventional pilocarpine that must be used every six hours,
because accumulation tollowing multiple doses could reach a toxic level. The
large amount of drug that is necessary for achieving the requited therapeutic
response Ieads to local and systemic toxicity.[6, 7]
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ii Long-acting dosage forms
fa) Definition
Based on their release kinetics, long-acting dosage forms can be
categorized into three major types: sustained action, prolonged action, and
repeat action dosage forms. The many techniques that can be used to obtain
the desired drug release characteristics depend on many factors, such as
drug properties, route of administration, and physiological and pathological
factors.[6, 8J
f i) Sustained action dosage
Sustained release dosage torms are designed to release a loading dose
of the drug, that is, the amount of drug required to provide an initial
therapeutic response followed by a maintenance dose to achieve an
optimum and consistent therapeutic response for a desired period of time.[6J
(ii) Prolonged action dosage forms
Prolonged action dosage forms are formulated to deliver enough drug to
provide a therapeutic response over a longer period of time than
conventional dosage forms.[6]
(iii) Repeat action
Repeat action dosage forms are designed to provide a dosing system
that releases an initial dose of drug followed by another single dose at a later
time.[6]
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(b) Advantages
Sustained release systems are used to minimize the problem of patient
complïance by decreasing the number of doses that a patient must take and
by minimizing the side effects and toxicity of drugs by eliminating or reducing
the blood level fluctuations associated with rapid release dose forms. Drug
activity can be prolonged over a number of hauts to enable patients to sleep
through the night, an effect that is particularly desirable with psychiatric
patients. Patients accept long-acting dosage products compared ta
conventional dosage form products. As in the case of Aminophylline, patient
acceptance of a drug product can be very important.[6J
f C) Disadvantages
Cost differences between twa formulations might have important bearing
on product selection when the clinical responses of the long-acting dosage
torm and those of the conventional dosage form do flot differ substantially, as
with Meprobamate. The slow clearance of some drugs might be a problem
that leads to toxic levels. The variability of absorption among patients may
reduce the predictability of the therapeutic response. A drug such as
riboflavin is absorbed high in the intestinal tract, thus rendering a prolonged
dosage form of it unnecessary. Accidentai or intentional poisoning with long
acting dosage form requires speciai treatment that conventional dosage
forms do not often require.[6]
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iii Controlled release
(a) Definition
Prolonged action duration may be a major consideration in designing a
controlled delivery system for high dose, Iow toxicity drugs with relatively long
biological haif-lives. In order to obtain optimal therapeutic efficacy with
minimal side eftects, however, some drugs may require that the release
kinetic from the dosage form be predictable and reproducible, particularly
drugs with a narrow therapeutic index.
Controlled release systems offer three different release rates. In zero
order release, the release remains constant until the system is depleted. In
first-order release, the release is proportional to the amount of drug
remaining in the system. In the third type of release, the rate of release is
proportional to the square root of time, a system in which a large amount of
drug is released tollowed by the release of substantially smaller and
decreasing amounts du ring the last half-life of the system.
Controlled release is a technique or method used to deliver the drug to
the site at a predetermined rate over a desired period of time.[4, 9] In
general, the controlled release of a drug to a specific site can occur through
one of the following methods: diffusion through a rate-controlling membrane;
the use of osmotically regulated tlow; or the chemical degradation or erosion
of a matrix in which the drug is incorporated.
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Each of these methods has unique characteristics that must be
considered in system design. Therefore, these methods are used to achieve
a number of goals:
1 .The design of a drug delivery device that uses zero-order kinetics,
through which the rate of delivery can be moditied by changing
membrane thickness and/or area or composition.
2.The design of a device where such a mechanism not only releases
the content by zero-order kinetics but can also sustains high
delivery rates that cannot be achieved using membrane
moderated devices.
3.The design of a drug delivery device with a predetermined lite that
would preclude the need to remove the device after comptetion of
its drug delivery rote [9, 10]
There are a number of assumptions to be considered in explaining the
dissolution and diffusion of a highly water-soluble drug f rom a porous planar
surface composed of a hydrophobic polymeric matrix. The assumptions are
the tollowing: the initial drug loading exceeds drug solubility in the polymer;
molecutar diffusion is the only mass transport mechanism; water-filled pores
are the only path by which the drug diffuses through the matrix; the diffusion
coefficient of the solute is represented by the integral diffusion coefficient;
sink conditions exist in the release environment; ail of the dispersed drug is
accessible for diffusion; and drug particles are homogenously dispersed in
the matrix and are smali compared to the diffusional distance. [11]
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(b) Rate control
The rate of delivery can be controlled with various techniques to improve
drug bioavailability, safety, compliance, and efficacy, some of which include
the following. First, rate preprogrammed drug delivery systems
preprogrammed the release of the drug from the delivery systems at a
specific rate, such as polymeric matrix. Second, activation-modulated drug
delivery systems activate the release of drug from this system through some
physical, chemical, or biochemical process and! or facilitate its release
through an external energy supply, such as osmotic pump, magnetic and
ultrasound energy. Third, feedback-regulated drug delivery systems use a
triggering agent, such as a biochemical substance in the body, to control the
release of the drug. This system also regulates the release of the drug
through biochemical substance concentration via some feedback
mechanism. [12, 13]
(c) Location control
Many drug delivery systems aim to control release at a specitic site of
action in the body. A targeting drug is one of location control applications.
Gene and protein delivery therapy is a potential application of a localized
delivery system to improve treatment and decrease the side effects. [12, 14,
15]
(d) Advantages
Controlled release drug delivery systems offer many advantages over
conventional drug regimes, such as optimized drug input rates into
8
systematic circulation in order to achieve the optimum therapeutic goal, a
lower drug level through local drug delivery, reduced side effects, less
trequent administration, no need for follow-up, and improved patient
compliance and comfort. Nove) drug Uelivery systems can be tormulated that
can provide delivery systems with greater safety and efficacy than
conventional delivery systems. [161
(e) Dïsadvantages
For particular formulations, the cost of fabrication due to expensive
ingredients and/or equipment is relatively high. Dose dumping, which is the
sudden release of a high amount of drug due to delivery system failure can
lead to systemic toxicity.[1, 61
b) Classification of controlled drug delivery systems
A number 0f designs of controlled release systems have been developed
to offer distinctive release profiles. Each requires a unique method for its
fabrication.[4, 7]
I Mechanïcal pumps
Mechanical pumps have been used for a number of pharmaceutical
applications. Mechanical pumps can be used to deliver drugs at a constant
rate over prolonged periods. They were developed for drug infusion, but
recently miniaturization has enabled the design and manufacture of
implantable pumps to deliver Insulin and Heparin.[7, 17]
9
ii Osmotic pumps
Osmosis is one ot the different approaches that can be used to control
drug delivery. Osmotic devices can deliver any drug, regardless of molecular
weight and chemical composition. Osmotic mechanisms provide the
opportunity to produce generic systems that operate independent of drug
properties. Osmotic devices offer constant delivery rates much higher than
diffusional devices. The Aiza Corporation manufactures two types of osmotic
devices. In the tirst device, the drug is placed in an inner and impermeable
flexible reservoir surrounded by osmotic agents, and the reservoir is
surrounded and sealed inside a rigid cellulose acetate semi-permeable
membrane. In the other device, the drug and the osmotic agent are
compressed into a cote tablet, film coated with a rigid semi-permeable
membrane containing a delivery orifice.[1, 4]
iii Chemically controlled systems (bïodegradable)
In this system, a chemical reaction is used to control the rate of drug
release f rom the polymer. Chemical reaction includes enzymatic, hydrolytic,
and ionization or protonation. Biodegradable devices do flot require surgical
removal, thus rendering them useful as implantable dosage forms. The
transformation of water-insoluble materials into water-soluble materials leads
to bioerosion, which can be divided into three types. In the first type, erosion
occurs through the cleavage of cross-Iinks or the water-soluble backbone.
During bond cleavage, the matrix wilI begin to swell and eventually dissolve.
However, the excessive swelling of polymer limits its applications. In the
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second type, protonation or ionization and hydrolysis are involved in
changing water-insoluble macromolecules into water-soluble
macromolecules, such as polyethylene glycol, polyethyleneimine and
polyacrylic acid. Because no backbone cleavage takes place, the
solubilization does flot result in any significant change in molecular weight.
However, unless the backbone is also degradable, polymers in this class are
only useful in topical applications that have no difficulty eliminating high
molecular weight and water-soluble macromolecules. In the third type, the
hydrolysis of labile bonds in the polymer backbone occurs in high molecular
weight polymers. Because the polymers in this class converted to small,
water-soluble molecules, the principle application of these polymers is for the
systemic administration of drugs trom subcutaneous, intramuscular, or
intraperitoneal implantation sites. [1, 18]
fa) Drug encapsulated with a polymer
Polymer-surrounded drugs in the core have been under development.
Simple polymer hydrolysis takes place without enzymatic hydrolysis. The
fabrication ot a polymer wïth different molecular weights can adjust the
degradation time of the polymer to obtain a wide range of delivering times.
Such a delivery system has been developed for use in a variety of
pharmaceutical applications, such as the delivery of a sub-dermal
contraceptive steroid.[1]
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(b) Drug coupled to polymer pro-drug
The polymer containing the bound drug can act either as a depot or as a
carrier. In depot mode, the polymer is Iocalized at a certain body site, and the
drug is released slowly through the cleavage of its attachment to the
polymeric backbone. The backbone of the polymer must undergo a cleavage
reaction to prevent high molecular weight residues in the body after drug
release. Carriers can offer a unique mode to deliver the drug to specific body
sites. In this case, the water-soluble polymer carnes a homing group in
addition to the bound drug. [1]
(c) Drug dispersed in polymer matrïx
When the solubility of drug molecules in the polymer is very slow, the
drug is uniformly dispersed throughout the polymer, exhibiting a release that
is controlled by the diffusion ot the drug through the polymer matrix and/or
the dissolution ot the polymer. The dispersed molecules are in equilibrium
with dissolved molecules. Properties of polymer and drug are determined
through the diffusion of drug within the matrix. As the drug is removed trom
the surface ot the device, more drug molecules diffuse f rom the interior to the
surface in response to the decreased concentration gradient leading to the
surface. The selection of a drug-polymer combination depends on numerous
factots, such as drug concentration, drug solubility in the polymer, polymer
water coefficient, diffusion coefficient, and geometry of the system. This
system is used to deliver drugs with 10w doses that exhibit short half-lives.
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Dispersed systems has been used, such as methamphetamine
hydrochioride in sustained release tablet, vaginal implantation of
contraceptive agents, and Norgestrel attached to intrauterine devicej4, 191
iv Diffusion-controlled devices
These devices are characterized by their primary release mechanism,
the diffusion of the drug through the polymer into the surrounding medium.
Diffusion-controlled release can be found in two basic designs;
monolithic devices and reservoir devices.[1]
fa) Reservoir devices
In the reservoir device, a core containing a drug is surrounded by a
polymeric film that acts as a rate-controlling permeabte membrane. A
reservoir device offers a constant release over a considerable period of time,
only if an excess amount of undissolved drug is available.[1, 191 A reservoir
device can be used to prepare a delivery system with high drug loading
levels. Different release rates can be obtained by controlling the thickness
and thickness and permeability of the membrane. Based on drug
concentration in the device, two types of reservoir release rates can be
obtained. First, in the case of zero-order release or constant release, the
concentration gradient is the driving force for drug diffusion. The release rate
depends on maintaining drug concentration in the reservoir at the saturation
level. The preparation of a saturated solution of drug with an excess amount
of undissolved solid drug to maintain the saturated level yields a reservoir
device with zero-order release behavior. Secondly, the graduai decrease of
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the concentration gradient over time leads ta non-zero-order release
behavior. A reservoir device is habitually more expensive than other systems
because of the parameters that need to be controlled, such as membrane
thickness, area, and permeability of membrane.[1, 7]
(b) Monolithic devices
In a monolithic device, the drug is mixed thoroughly in a rate-controlling
polymer. The drug is then incorporated into a polymer matrix, through which
passage to the surface occurs either by diffusion through pores within the
matrix structure or by diffusion though the polymeric phase itself.[7, 19]
Simplicity of fabrication is one advantage of using the monolithic device.
Furthermore, it avoids massive drug release due ta rupture of the polymeric
coat. [7]
fi) Monolithic solid solution (dissolved drug)
Monolithic solid solution is a delivery system in which the drug dissolved
in the polymer must be below drug solubility level in the polymer. It can take
the form 0f a sphere, cylinder, or slab. Penetration of the solvent into the
polymeric matrix contraIs the dissolution rate.[19J The drug release rate f rom
a monolithic device can be calculated according ta the kinetic release of this
system in twa steps. Early time release is used ta calculate the first 60% of
the release, after which the late time release occurs. For the early part, the
release is proportional to Urne square root. If the initial drug concentration is
increased, the system could change f rom a dissolved system into a
dispersed system. [7]
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(ii) Monolithic dispersion fdispersed drug)
A monolithic dispersion device is a delivery system in which the drug is
dispersed as a sollU particle within the polymeric matrix.[7] Low drug
solubility in the polymer causes the dissolution of a small amount of the drug
and the homogenous dispersion of a large amount of the drug within the
polymeric matrix. Monolithic dispersion systems are classif jeU in three types,
based on the drug loading level.[7, 191
(a) Simple monolithic dispersion
For non-biodegradable polymers, Urug loading levels, the volume of
which can range from 0% to 5%, can have a significant effect on release
kinetics. The drug is dissolved from the polymeric medium and is then
diffused to the surface of the device. [7J
(b) Complex monolithic dispersion
Drug loading level volumes range trom 5% to 10%, and the drug release
mechanism is more complex. Drug particles torm cavities near the surface of
the device, which are tilled with fluid imbibed from the dissolution medium.
The cavities offer favored pathways for drug particles that remain within the
device. In a complex monolithic dispersion device, cavities are flot connected
to form continuous pathways to the surface; rather, they may increase the
overall apparent permeability of the drug in the device.[7]
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(c) Monolithic matrix systems
With drug loading volumes of approximately 15% to 20%, drug particles
dispersed in the polymeric matrix corne in contact with one another. When
the volume of dispersed Urug concentration exceeds 20%, the cavities
formed by drug particles during the dissolution are sufficiently numerous to
form a continuous channel to the matrix surface. In the monolithic system,
the majority of dispersed drug particles are released by diffusion through
these channels. The solubility and diffusivity of drug particles in dissolution
mediums filling the channels determine the drug release rate.[7]
2. Polymer matrices for the controlled release of drugs
Polymer matrices for controlled release are classified into three groups,
water-soluble, biodegradable, and non-biodegradable polymers.[1 81
Polymeric materials used in a polymeric matrix must provide the
desirable release rate, be compatible with the drug and the body, and be
biodegradabte.
a) Classification of polymeric matrices
Polymeric matrices used as drug delivery systems are classified in three
basic types.
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i Water-soluble polymers
Ethyleneoxy, amine, and carboxylic acid, the polymers that contain
hydroxyl, are frequently used as drug delivery matrices. In the body,
polymers with hydroxyl or ethyleneoxy groups are dissolved as a resuit of
hydration, and polymers with amine or carboxylic acid groups are dissolved
as a resuit of ionization or protonation. Water-soluble polymers dissolve in
water as a resuit of protonation or ionîzation; they can be used for controlled
drug delivery in gastrointestinal tract. Polyethylene glycol, polyethyieneimine,
and polyacrylic acid are examples of such polymers. Since water-soluble
polymers dissolve quickly in biological fluids, water-soluble polymers are
usuaily used for short-term (several hours to several days) drug delivery. [18]
Many drugs are either poorly absorbed in the stomach or destroyed by
acidic fluid; to increase efficacy, these drugs can be formulated as tablets or
capsules with polymers of hait esters of maleic anhydride.
Water-soluble polymers are used as aqueous solutions for drug delivery.
Atter polymer dissolution, the polymer increases the viscosity of the drug,
which leads to longer drug retention in the desired application. This
technique is commonly used with the ocular, nasal, and oral application of
drug solutions. [20, 21]
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ii Non-biodegradable polymers
Because these polymers are basically inert in the body and do flot
undergo any chemical reactions therein, non-biodegradable polymers can be
used for extended drug delivery. Due to their biocompatibility and higher
permeability of many drugs, silicones are excellent materials for drug
delivery. Silicone has also been used in various drug deliveries, which has
lead to the commercialization of silicone for such items as transdermal
devices for nitroglycerine and contraceptive steroids. The Urug release rate
from drug delivery systems made of silicone matrices or reservoirs can be
modulated according to the Fickian theory. [181
iii Biodegradable polymers
Bioerodiblity is the ability of the polymer to degrade to control drug
release rate. In this context, the term “biodegradable polymers” refers to
water-insoluble polymers that are gradually converted in the body into water
soluble materials by chemical reactions. Since degradation involves chemical
reactions that usually occur over a long period of time, these polymers can
be used for Iong-term drug delivery. Different methods can be used ta
change water-insoluble polymer into water-soluble materials in the body.[18,
22]
In the first method, a side chain that undergoes hydrolysis in the body ta
produce hydroxyl, carboxyl, or other hydrating groups can be added to a
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polymer chain. Therefore, these groups act to make the entire polymer
water-soluble. The second method is to crosslink a water-soluble polymer
with a hydrolysable cross-linking agent. The polymer becomes water-soluble
once it is placed in the body. In the third and most frequently used method,
water-soluble polymers bouse hydrolysable functional groups directly in the
polymer chain. Upon hydrolyzation of such groups, the polymer chain is
slowly reduced to increasingly shorter segments that tinally become water
soluble. In this case, an extremely high-molecular-weight polymer with good
mechanical properties can be used. In this case, the polymer is eliminated
f rom the body when the polymer chain is reduced into water-soluble
fragmentsjl 8]
Even though many examples of the f irst two categories have been
evaluated for drug delivery, problems, such as controlling the hydrolysis rate
of the side chain groups and preventing the reaction of side chain groups
with the drug itself have occurred. Moreover, it is very difficuit to provide
enough cross-Iinking to make the polymer insoluble but also degradable
within a reasonable period of time. In the other biodegradable polymers, the
polymer chain of the water-soluble segment must be less than (50,000)
Daltons in order to achieve proper elimination trom the body. Because of the
disadvantages of the f irst two categories, the third category of biodegradable
polymers has received more attention for drug delivery applications.[1 8]
Aliphatic polyesters prepared f rom lactic and glycolic acids are widely
used in various applications as synthetic biodegradable polymers.
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Homopolymers and copolyrners of lactic and glycolic acids have been
studied. Ihose polymers have Food and Drug Administration approval to be
used for drug delivery matrices. The commercial availability of polylactic acid
and polyglycolic acid as well as the ability to accurately control their
biodegradation rates make these polymers the first choice for biodegradable
polymers.[1 8]
Different degradation tirnes of biodegradable polymers afford a wide
range of applications for those polyrners as drug delivery matrices. The
degradation time of aliphatic polyester hornopolymers in vivo normally ranges
from one to two years, depending on crystallinity and hydrophobicity.
Polyanhydrides and polyorthoesters are other series of biodegradable
polymers which depend upon chain degradation.[181
Polyanhyd rides and polyorlhoester polymers contain hydrophobic units
that loin along polymer chains by functional groups and are subjected to
hydrolysis. Because of the nature of those polymers, water only breaks
through the outer layers when the polymers are implanted in the body. The
outer layers’ contact with water causes quick hydrolysis of the water-labile
linkage, followed by the degradation and loss of the outer layer of the
polymer. After the loss of the outer layer of polymer, another layer cornes in
contact with water and the process continues until the polyrner is gradually
eroded from the sur[ace.[18J
The rate of hydrolytic degradation at the surface of polyanhydrides and
polyorthoester polyrners s much faster than the perrneation rate of water into
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the matrices of those polymers. The pH solution increases as the
degradation rates of the copolymer and homopolymers increases. In many
examples of drug release trom these polymers, the drug release rate has a
good correlation with polymer degradation or erosion. In some examples of
compression-molded release, drug release has been faster than polymer
erosion, probably because of inhomogeneous drug dispersion or a
microporous structure. These polymers protect drugs susceptible to
degradation in the body and deliver the drug at a constant rate in an active.
This maintains the polymers’ usability in different applications.[Ï 8, 20-251
3. Polylactic acid as drug carrier
a) Physical and chemical properties
The presence of a methyl group on the alpha carbon of polylactic acid
differentiates the polylactic acid chem ically, physically, and mechanically
from polyglycolic acid, even though the two are structurally very similar.
There are many factors such as the ester Iinkage due to presence of the
methyl group; the molecular weight; degree of crystallinity, and the physio
chemical environment, which make the polylactic acid more hydrotically
stable than polyglycolic acid. The chirality at alpha carbon of polylactic acid
makes it possible for the polymer to exist as L, D, or DL isomers. A racemic
mixture of L (-) lactide and D (-i-) lactide isomers is used to prepare DL-PLA,
while L-PLA is made trom L-Iactide and D +PLA is made f rom D+ lactide.[26,
271
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b) PoIy (L-Lactic acid)
L- Polylactic acid has a melting point (1m) of approximately 175°C and a
glass transition (Tg) of approximately 65°C. It is a biodegradable, crystalline
polymer. Its tensile strength is (10,000-15,000 psi) and its modulus of
elasticity is (500,000 psi), which results in a more crystalline polymer. The
crystallinity of L-PLA is reporled in the range of 35%, which makes it Iess
than that of PLG. L-polylactic aclU is so’uble in organic solvents, such as
chloroform, and has a specitic gravity of approximately 1.2-1 .3.[24, 28, 29]
Solid-state polymerization is used to prepare poly (L-lactic acid) with a
very high-molecular-weight polymer (1 ,000,000). When polymerization
temperatures are lower than the melting point of the polymer, solid-state
polymerization is obtained as a resuit of the crystallization cf the polymerizing
polymer.
Stannous octoate or stannic chloride dehydrate are used as catalyzers in
the polymerization of L-polylactic acid.[26, 27, 30]
c) PoIy (DL-Iactïc acid)
On the other hand, DL polylactic acid has a Tg ot approximately of 57°C.
It is a completely amorphous polymer with a specific gravity of approximately
1 .2-1 .3, which is similar to that of L-PLA. L-polylactic acid is less accessible
to hydrolytic attack than DL-polylactic acid, which makes the DL-polylactic
acid polymer degrade faster than L-polylactic acid polymer. DL-polylactic
acid has a much lower tensile strength (5,000 psi) than L-PLA and PLG and
a modulus of elasticity of (250,000 psi), probably due to the lack of polymer
crystallinity. Temperature ranges of 135-155°C are typically used in DL-PLA
polymerization. Because it is an amorphous polymer, solid-state
polymerization cannot be achieved with L-polylactic acid. The reaction can
be catalyzed by stannous octoate or stannic chloride dehydrates. Chain
control agents, such as water, primary alcohols, amines, or other active
hydrogen compounds are used to control the molecular weights of PLA. Tri-
or poly-functional chain-control agents are used to prepare branched
polymers. Alcohols, such as 1-dodecanol or 1- or 6-hexanediol, which have
functionalities of less than two, are used to prepare linear polymers.[24, 26,
27, 30]
U) Preparation
Direct polymerization trom linear monomers or oligomers of lactic acid
might be used, but this yields a polymer with a limited molecular weight. For
most applications, using cyclic dimers as starting materials is the optimal
method for polymer and copolymers. The two methods are explained below.
[26, 27, 30]
j Direct polymerïzatïon
Low molecular weight polylactic acid can be prepared through the direct
polyesterification of lactic acid. Because water can effect the condensation of
a-hydroxycarboxylic acids, water is removed f rom the reaction mixture by
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boilïng the water or by performing azeotropic distillation with an aromatic
hydrocarbon solvent.[26, 31]
Adding an acid catalyst at a temperature below 120°C ïncreases the
reaction rate; however, above 120°C, water removal is a rate-limiting step, so
there is no benefit of adding a catalyst. Reactants with known purity and
stability are necessary for an efficient reaction. The presence of
monofunctional impurities in the reactants can terminate the polymer chain.
In order to prepare a chain with 100 mer units, the impurities must be less
than 1%. b prepare a lactic acid polymer with high molecular weight 0f
(10,000) or higher, it is necessary to use the cyclic monomer of lactide rather
than the direct condensation method. [26]
ii Polymerization via cyclic monomers
When high-molecular-weight polymers are required, polymerization via
cyclic monomers has many advantages over the direct method. Contrary to
direct polymerization, this method does not require a high degree of
dehydration. Cyclized or linear forms of the polymer can be differentiated by
their physical properlies. Moreover, monofunctional impurities can be
reduced and stoichiometry, assured. Acid catalysts and certain
organometallic compounds are the most useful catalysts. [26]
The formation of polylactic acid from lactide can be written as follows:
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CH31Ç CH3O
+ H HO—CH-COHU 2 Ly CH3 2fl
o
Equation 1: Preparation of polylactic acïd from lactide
In the polylactic acid preparation illustrated in Equation 1, one mole of
polymer is formed for each mole of water added to the reaction mixture.
Because each mole of catalyst contains one mole of water, the number of
moles of polymer produced at equilibrium equals the number cf moles of
catalyst added. It is useful to use organometallic catalysts, such as diaikyl
zinc, trialkyl aluminum or tetralkyl tin complexes, to prepare polymer with an
average molecular weight of 40,000 or greater.[26]
e) Biomedical applications
Polylactic and polyglycolic acids and their copolymers have recently,
been used as matrices of drug delivery and as excipients for the sustained
release of drugs. The formation of surgical mesh, sutures, woven or knitted
tubular or vascular grafts comprised of copolymer fibers, absorbable staples,
solid prostheses used as cylindrical pins and screws, and reinforcing plates
are furiher applications of polylactic and polyglycolic acids and their
copolymers.[26, 30, 32-35]
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j Utilization as sutures
This application has generated the most valuable information about
biocompatibility and biodegradability. Polylactic acid and polyglycolic acid
polymers have a littie or no residual effects on tissues. Very slow shrinkage
when it is combined with PLG might cause lactic acid with optical isomers of
pure L(+) or D(-) to be chosen over D,L-lactic acid.[26, 30, 34, 35]
ii Use as prostheses
Based on the purpose of those preparations, different proportion of PLA
and PLG or pure forms of one or the other are used to achieve the desired
implant degradation time. Faster polymer degradation is obtained using DL
PLA rather than L (+)-PLA
When polylactic acid and polyglycolic acid polymer are used in
implantation, there is no toxic, inflammatory, or tissue reaction reported.
Moreover, this method renders surgical removal unnecessary. The
degradation products of those polymers have none of complications that
occur with conventional implants such as corrosion, foreign body reaction,
and migration after being left for a long time in the body.[26, 30, 32, 33, 35]
iii Using the polymer as a carrier system in implantation
Implants prepared f rom polylactic acid and polyglycolic acid polymers in
forms such as fibers, pressed tablets, extruded forms, or films are used in
controtled drug delivery [36]
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ta) Fibers
Biodegradable tibers are prepared trom polylactic acid, and can take the
form of solid fibers or hollow ones. These fibers are given subcutaneously,
using special needles. The drug delivery rate of the hollow fiber depends
strongly on the structure membrane ot the wall. Hollow tiber systems can be
used with any drug that can be made in an aqueous solution. Such systems
are interesting because of their ease of use and their ability to release the
drug in a controlled manner; however, such reservoir systems always carry
the risk of “dose dumping” as a resuit of membrane failure.[36]
(b) Tablets
A direct compression method, at either ambient or elevated temperatures
and with or without added solvent, is common for preparing polylactic and
glycolic acid tablets for implantation. Most compression methods are based
on traditional pharmaceutical techniques, which are limited to low-molecular
weight polymer with glass transitions at approximately 30°C. Unless a
solvent is used, this allows for the fusion ot individual partictes and the
integration of polymer and drug upon compression.[36J
f C) Extruded implants
Extruded matrix delivery systems disperse a drug in a polymeric matrix.
These devices usually take the form of cylinders. They can be used as
monolithic matrix release systems or be coated with polylactic acid to limit
degradation and subsequent drug release.[36J
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(d) Films
Films are prepared simply by dissolving the polylactic acid polymer in a
solvent, such as chloroform or acetone dichloromethane, and then adding
the drug to obtain solution or suspension.[36]
f) Some factors that affect drug release rate from polymeric matrices
i Drug loading
Since sustained release and controlled drug release have been the focus
of pharmaceutical research, the polymeric matrix has received most interest.
After Higuchi’s work (1963) on the release of drugs f rom polymeric matrices,
more effort is being devoted to the study of the parameters that affect release
f rom the polymeric matrix. Drug loading has a potential effect on release f rom
the polymeric matrix. A drug loading level (high or low) within the polymeric
matrix can be treated with either a porous matrix or a non-porous matrix
system.[37, 381
ii Porosity
Generally, porosity is the volume of void spaces in a given material. It is
the inter- and intra-pore space. For a matrix device, porosity is defined as the
part of the matrix that exists as pores and channels that liquid can penetrate.
Different instruments can measure porosity based on the characteristic
information of the sample ta be measured, such as density, gas adsorption,
water displacement, and porosimetry. Mercury intrusion permeability is used
when the actual pote size distribution is needed. Helium pycnometry and
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mercury porosimetry are other methods for porosity determination. Drug
release can be modulated by controlling porosity through pore size and
volume fraction.[39-43J
iii Particle size
Unless the particle shape is defined, identifying the particle shape is very
difficuft. There is no unique diameter for particles. An equivalent spherical
diameter that relates the size of a particle to the diameter of a sphere with
the same surface area, volume, or diameter is used to calculate particle size.
There are different methods for measuring particle size. Some of the most
common methods are microscopy, screen (sieve) analysis, electronic
counting (Coulter, Malvern), sedimentation (Andreasen apparatus),
permeametry (sub-sieve sizer), and reflectance FTIR (Otsuka and Mastuda,
1996). [39, 40, 43]
iv Effect of plasticïzer on drug release from polymeric matrix
fa) The effect on the polymer
Polymers are used to coat tablets and beads. The plasticizer improves
the physical properties of the polymer by reducing brittleness, improving f low,
and increasing toughness, tear resistance, and strength. The glass transition
of the polymer can be reduced by adding the plasticizer. The amount and
type of plasticizer and the reaction between the polymer and plasticizer will
determine the degree of plasticization. Increasing the flexibility of the polymer
depends on the degree at which the plasticizer affects the intermolecular
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attractions, thus increasing the mobility of the molecules. The plasticizer
affects the rate of release by changing the water permeability of the polymer.
It also decreases polymer-polymer interaction and can improve the
mechanical properties of the polymeric matrixj44-48J
(b) The effect on drug release
The type and amount of plasticizer have an important influence on the
drug f rom the polymeric matrix. The plasticizer increases the drug release
trom the polymeric matrix by increasing the mobility of the polymeric chain. A
plasticizer can also influence the physicochemical characteristic of the
polymer, which, in turn, affects the permeability rate of some molecules.
Permeation occurs because the plasticizer agents can weaken the
intermolecular forces between the polymer chains. The presence of
plasticizers reduces polymer-polymer interactions, thereby increasing the
mobihty of polymer chains and, consequently, drug permeation 145, 48]
4. Microspheres
a) Introduction
Microspheres are polymeric entities that faIl in the range of 1-1000
micrometers. They are porous microparliculate drug Uefivery systems that
promote the controlled release ot drugs. They represent a polymeric matrix
system containing the drug uniformly distributed throughout the polymeric
matrix. Microspheres are one method of representing the polymeric matrix
systems with unitorm drug distribution. Both natural and synthetic polymers
j
are used for microsphere preparation. Drug and polymer properties are
crucial tactors for choosing a suitable method of microsphere
preparation.[49, 50J
A number of methods are used for microsphere preparation, each of
which has its own advantages and disadvantages. Microsphere
characteristics are influenced by the chosen preparation method.[51]
b) Methods of preparation
i Spray-dryïng technique
The spray-drying technique has been widely used in the pharmaceutical
industry. The technique has recently been used to prepare microparticulate
drug delivery systems. Spray drying is an attractive technique because the
rapid, single-step method is suitable for sensitive drugs. lt consists of
spraying a suspension or a liquid through a nozzle in a drying chamber to
obtain spherical solid particles. The structure of microparticles will be
determined based on the polymeric solution that will be sprayed and on
whether the drug is dispersed or dissolved in the polymeric solution.
Microspheres are obtained by spraying a solution of the drug and the
polymer, while microcapsules are obtained by spraying the polymeric
solution in which the drug is suspended. [49]
ii Solvent evaporation
The evaporation of an organic solvent is another method for microsphere
preparation for controlled drug release. Microspheres can be prepared by
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dispersing ou droplets that contain the drug and the polymer. The organic
solvent is chosen based on the physicochemical properties ot drug. A double
emulsion is frequent)y used. First, the aqueous phase is prepared by
dissolving the drug in water for encapsulation. DCM (dichioromethane) is
used as an organic solvent, and the aqueous phase is dispersed in the
solvent, which contains a biodegradable polymer to prepare the first W/O
emulsion. An aqueous stabilizer is used to prepare the second OiW
emulsion. The microspheres are formed when the DCM is evaporated, and
the hardening of the polymer causes the encapsulation of the drug.[52, 53]
iii Solvent extraction
The preparation of microspheres by solvent extraction generally consists
of dispersed or dissolved drug in an organic solvent that contains the
polymer. The organic phase is then emulsified in another immiscible, often
aqueous phase, followed by an extraction process to obtain microspheres
from the droplets of the organic solvent. The organic solvent of the dispersed
phase of the emulsion is eliminated by two stages. In the first stage, the
solvent extraction is the diffusion of the solvent in the dispersing phase. In
the second stage, solvent evaporation is the elimination of the solvent at the
dispersing phase-air interface.[54]
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5. The drug model pentoxifylline
o CH3
N
*—N
Empirical formula C13H18N403 Molecular weight 278.31
Pentoxifylline has a melting point range from 105°C to 106°C and is
very soluble in acetic acid; freely soluble in chloroform, methanol, and
acetone; sparingly soluble in ethanol; slightly soluble in ether; and
practically insoluble in hexane. Pentoxifylline decreases blood viscosity,
thereby improving blood flow probably through its effect on erythrocyte
deformability, platelet adhesion, and platelet aggregation. It is also
thought to improve the oxygenation of ischemic tissues. Pentoxifylline is
used mainly in the treatment of peripheral vascular disorders. It has also
been used in cerebrovascular disorders. The reason for the choice of
pentoxifylline as a drug model was to continue a previous project in the
laboratory. The objective of the project is to design an oral modified
release form (reservoir type) for the release of pentoxifylline over a
period of at least for 48 hours to treat a Founder afoot. Founder foot is a
horse disease characterized by a reduced microcirculation of the foot
leading to lameness. The administration of pentoxifylline improves
circulation, reducing the symptoms and prolongs the useful life of the
animal. [55, 56]
B. Objective
The objective of this project is to develop and characterize plasticized
film formulations containing mixtures of high and Iow molecular weights of
polylactic acid with different drug loading levels.
The specific objectives are as follows:
1. To develop and optimize a plate-coating process technique that will yield a
homogenous film.
2. To develop and characterize a formulation that could be transformed into
a dosage form to be used in vivo.
3. b evaluate the effect of formulation process parameters, such as drug
loading and plasticizers on in vitro release kinetics
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II. Materials and methods
A. Materials
Chemicals
High-molecular-weight PLA 252000, lot number 516988, was brought
from (Polysciences, mc). Low-molecular-weight PLA 64800, lot number R-
02051 0, was purified from previously synthesized PLA in the laboratory.
Pentoxifylline with lot number 18P0334 was used as drug model.
Dichloromethane (solvent grade) with lot number A04814 was brought from
J.T. Baker and was used as a solvent for the polymeric solution. Chloroform
lot number 001173, (HPLC) grade was brought from Laboratoire Mat and
was used as a mobile phase of Gel Permeation Chromatography (GPC).
Acetone (99.5% histological) grade, lot number 00648DB, was used in low
molecular-weight PLA purification. Polystyrene with different molecular
weights were brought from Polysciences Inc and were used as standards for
PLA molecular weights determination. The different molecular weights were
as follows: molecular weight 20,000, lot number 430232; molecular weight
50,000, lot number 431655; molecular weight 90,000, lot number 432010;
molecular weight 200,000, lot number 412702; molecular weight 400,000, lot
number 431655; and molecular-weight 600,000, lot number 414884. Sodium
phosphate dibasic A.C.S reagent, lot number 083K0120; sodium chloride
crystal A.C.S reagent, lot number M35589; and potassium phosphate mono
basic crystal A.C.S reagent, lot number M37148 were brought from
J.T.Baker, Inc and were used for phosphate buffer preparation.
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2. Equïpment
Compressed air (80 psi) was used with a spray gun (Badger250-4) that
was used to spray the polymeric solution onto stainless steel plates of
approximately 2cm x 2cm of known surface area and 0.6mm thickness. An
Ultrospec 2000 manutactured by Biocharm, Ltd. and a UV/visible
spectrophotometer 8452A Diode Array spectrophotometer manufactured by
Hewlett-Packard were used to measure drug release at wavelength 274nm.
Water gel permeation chromatography GPC model ALC-202 liquid
chromatographs manufactured by Waters Associates Inc were used to
determine PLA molecular weights. A differential scanning calorimetry (DSC)
Mettler TC Il TA processor manufactured by Mettler was used to characterize
low- and high-molecular-weight drugs as well as selected samples of films.
An electron microscope MA JSM-5900LV, manufactured by Jeol Inc.
Peabody was used to characterize the surface of selected film formulations
betore and after dissolution. Scintag XDS-2000, Si (Li) Peltier-cooled solid
state detector CuKalpha source at a generator power of 45 kV and amperage
of 40 mA was used to measure crystal peaks of the drug and the polymer in
selected film formulations.
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B. Methods
Characterization of PLA
a) Purification
Polylactic acids 0f 10W molecular weight were purified with 38.26 g of
PLA for the different molecular weights, as shown in Table 1. The PLA was
dissolved in 382 ml of 10% acetone in water at room temperature and stirred
for 30 minutes. The PLA solution was slowly poured into 4 liters of distilled
water under constant mixing at room temperature in 50 ml increments of
acetone in 500 ml of distilled water and then centrifuged at 3000 rpm for one
hour. After the separation of the supernatant, sodium sulfate was mixed into
the supernatant to precipitate the remaining PLA. The solid product was
dried for 24 hours over phosphorous pentoxide under vacuum to remove
residual solvents.
Weight MW MW Polydispersity
17.77g 32700 12000 2.73
16.70g 36600 17900 2.04
3.79g 35000 12600 2.76
Table f: Molecular weights data of 3 selected lots of PLA for blending
and purification.
b) Molecular weight determination by gel permeation chromatography
Molecular weight and polydispersity of polylactic acid samples were
determined by Waters Gel Permeation Chromatography (GPC) model ALC
202 liquid chromatographs (Waters Associates, Inc.). Gel permeation
chromatography Was performed WÏth chloroform as a mobile phase using a
Waters pump system connected to a differential refractive index detector and
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a Waters 730 data module. Two Phenogel columns with nominal porosities
ranging from 5um 10 to 5um 1 angstroms were used for ail samples and
polystyrene standards. A standard curve trom tive different polystyrene
molecular weights was created as it is shown in Figure 1. In order to obtain
the calibration coefficient, 5 mg of each standard was dissolved in 5 ml
chloroform and 100 I was injected. Atter the calibration coefficients were
obtained, 50 mg of each sample was dissolved in 5 ml chloroform and 50 pI
was injected to determine the molecular weight.
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Figure 1: Calïbration curve of polystyrene standards for the PLA
molecular weight determination.
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2. Preparation of the polymerïc solution and plate-coating process
a) Polymeric solution preparation
The polymeric solution was prepared by measuring 75 ml ot the
dichioromethane (DCM) solvent and then weighing the amount of drug
required to obtain the necessary drug loading. The drug was added to the
solvent by stirring at room temperature until a clear solution was obtained,
atter which the polymer was added to the solution by stirring for 40 minutes
until it was completely dissolved. Different drug loadings were prepared with
and without plasticizers. In the cases where the plasticizer was needed, the
right volume of plasticizer was added at beginning betore the drug is added.
b) Plate coating process
Stainless steel plates 2cm x 2cm in size and 0.6mm in thickness were
first cleaned once in 1 N HCL hydrochloric acid for 20 minutes and then put in
the solvent DCM for another 20 minutes. Four dried and cleaned plates were
arranged over a clean sheet for the coating process. The polymeric solution
that contained drug, the polymer, and the plasticizer was sprayed onto the
f irst side of the plates. A spray gun, Badger 250-4, was used as a spraying
system. A model 202 Oster air gun used as a source of hot air was directed
onto the plates after each spray to evaporate the solvent, to avoid
condensation of the moisture on the plates, and to produce a clear
homogenous film. The plates were weighed before and after the spraying
process to calculate weight gain and drug content of the film. Through
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numerous trials of spraying the polymeric solution containing drug and DBS
over the stainless plate and applying hot air to dry the film, the experimental
conditions such as spray time, spray distance, and drying time were
optimized. The quality ot compressed air is critical and must be f tee of
particulate matter, oll, and be anhydrous.
3. In vitro release study
A standard curve of the drug model with five different concentrations was
prepared using dilutions trom a stock solution. The plate containing polylactic
acid film was hanging down in the f Iask filled with a phosphate buffer solution
with a pH of 7.4. The flask was put in a thermostated water bath shaker at
37C°. Samples f rom the release solution were periodically removed f rom the
flasks using syringes. The drug released into the medium buffer was assayed
using a Hewlett-Packard 8452A Diode Array Spectrophotometer and
Ultrospec 2000 UVNisible Spectrophotometers (Pharmacia Biotech) at a
wavelength of 274 nm. The percent and amount of drug release were used to
evaluate the kinetics of release trom the different batches.
4. Polymeric film characterization
a) DSC scan ning
Thermal characterization was carried out using a Mettier TC Il TA
processor differential scanning calorimeter. Two heating runs up f0 200C°
and one cooling run at -40C° at 10 Klmin were performed. The melting point
(Tm) and the glass transition (1g) of polylactic acid samples and films with
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different levels ot plasticizer and drug loadings were determined. The sample
weights ranged from 4mg to 22mg. Aluminum sample pans were used.
Different samples of Iow and high molecular weight of PLA with and without
DES were prepared by dissolving the materials in the solvent DCM
(dichioromethane) and then evaporating the solvent.
b) Scanning-electron microscopy
The samples were mounted on aluminum stubs using carbon tape and
then examined directly (without conductive coating) in an MA JSM-5900LV
electron microscope (Jeol Inc. Peabody) using secondary electron imaging
with an accelerating voltage of 5-7 kV.
c) Powder X-ray diffraction
X-ray diffraction pattems were measured wîth a Scintag XDS-2000, Si
(Li) Peltier-cooled solid-state detector, CuKaipha source at a generator
power of 45 kV and amperage of 40 mA. Divergent beam slits of 2 and 4 mm
were used, as were receiving slits of 0.5 and 0.2 mm. Scan range was set
from 2 to 40 degrees 2 8 using the step scan mode at a step size of 0.02
degrees 2 8 and a count time 0f 2 seconds. Samples were placed on the low
background quartz disk. In order to obtain a good diffraction pattern, rather
than grinding the samples, the films of different samples containing low
molecutar weight PLA, 70%, 20%, and 60% drug and 10% DES were slightly
broken up. A high molecular weight PLA sample was used without grinding
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and a standard holder was used. The instrument alignment was verified
weekly using a corundum disk (NIST SRM 1976).
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llLResufts and discussion
A. Characterization of PLA
1. Gel permeation chromatography resuits
As shown in Table 2 and Figure 2, GPC resuits of PLA characterization
were obtained for the low- and high-molecular-weight PLA. The results
confirm the expected significant differences in molecular weight required for
this study.
Sample Mn Mw Mz D
Low
moleculai
weîght 25300 64800 445000 2.55
Hïgh
moleculai
weight 146000 252000 222500 1.72
Table 2: Data 0f low- and high-molecular-weight PLA characterized by
Gel Permeation Chromatography.
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Figure 2: Molecular weight distribution of low- and high-molecular
weight PLA.
2. Powder X-ray diffraction
Table 3 shows the diffraction peaks of pure pentoxifylline. Table 4
reports an X-ray diffraction characteristic of selected peaks of samples at
different drug loading levels (10%, 20%, and 60%) and a constant plasticizer
level (DBS) (1 0%) based on the intensity of four specific different peaks.
These peaks were selected on the basis of lack of interterence f rom the PLA
peaks. It shows that pentoxifylline sample peaks increase as drug loading
levels increase. Diffraction peaks of the drug (pentoxifylline) confirmed the
presence of the crystalline drug (pentoxifylline) dispersed in the matrix. Table
5 shows PLA diffraction peaks from the samples increasing as the drug
loading decreases.
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Scaftering Angle d-spacing (A) Relative Intensity
fdegree 2-O) III, (%)
6.77 13.0452 14.99
7.57 11.6683 50.56
11.45 7.7216 12.70
12.65 6.9916 44.28
13.57 6.5196 47.56
15.13 5.8507 100.00
15.18 5.6006 9.14
20.41 4.3475 13.00
21.69 4.0938 14.91
22.41 3.9638 11.69
24.05 3.6971 27.61
24.93 3.5686 6.76
25.69 3.4647 8.12
26.53 3.3569 9.83
27.85 3.2007 22.23
28.61 3.1174 7.81
29.85 2.9906 8.01
31.65 2.8246 7.74
32.41 2.7600 6.43
34.45 2.6011 12.64
35.13 2.5523 10.16
42.05 2.1469 5.60
45.61 1.9873 5.00
Table 3: Crystallography data from the X-ray powder diffraction paftern of
pure pentoxifylline.[55J
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Scaftering Angle Height of pentoxifylline Peaks
fdegree 2-e) 10% loading 20 % loading 60 % loading
13.57
- 0.35mm 0.65mm
15.13
- 0.25mm 0.35mm
24.05
- 0.45mm 0.75mm
28.61 0.2Omm 0.4Omm 0.6Omm
Table 4: Crystallography data of pentoxifylline from the X-ray powder
diffraction paftern of films with different pentoxifylline loading samples(10%, 20%, and 60%) at a constant plasticizer level (DBS 10%).
Scaftering Angle Height of PLA Peaks
fdegree 2-9) 10% loading 20 % loading 60 % loading
16.50 6.2Omm 2.6Omm 0.6Omm
19.00 1.6Omm 0.ZOmm
-
Table 5: Crystallography data of PLA from the X-ray powder diffraction
paftern of films wïth different pentoxifylline loading samples (10%,20%,
and 60%) at a constant plasticïzer level (DBS 10%).
B. Drug release studies
A USP dissolution system was used to evaluate the drug released f rom
different formulations of polylactic acid polymeric film. The effect of drug
loading with and without plasticizer on drug release was evaluated first. The
plasticizer was used to modify the physical properties and release
characteristics. Dibutyl sebacate was selected as the plasticizer on the basis
of prior research.[44, 48]
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Drug release from unplasticized polymerïc film
Drug released f rom different formulations containing 50% low- and 50%
high-molecular-weight PLA with different drug loadings (20%, 25%, and 30%)
was evaluated f rom spray-coated stainless steel plates immersed in a
dissolution fluid. Figures 3 to 5 show the dissolution results for the different
loadings. The results of the 20% drug toading show extreme variability of
drug release among coated plates of the same batch due to the eventual
cracking of the film. Film cracking occurs at variable times and to different
extents due to the film quality as shown in Figure 3 for different films
containing 20 % drug loading without DBS. The film for the various plates
cracked at 60 hrs (#1), 2 hrs (#2), at 48 hrs (#3), at 12 hrs (#4) and at 4 hrs
(#5). The extreme variability in dissolution for film plates f rom the same batch
makes the film without plasticizer makes this approach totally unreproducible
and unreliable for drug delivery. The cracking of the film leads to the
infiltration of dissolution media between the film and the plate, thereby
increasing the effective surtace area of dissolution leading to an increase in
the rate of release. Because of film cracking, an accurate evaluation cannot
be achieved for the drug release f rom the film without the plasticizer.
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Fîgure 3: Percentage of drug released as function of time(hrs) for films
containing 20 % pentoxifylline without plasticizer
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Figure 4: Percentage of drug released as function of time(hrs) for films
containing 25 % pentoxifylline without plasticizer
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Figure 5: Percentage of drug released as function of time (hrs) for
films containing 30 % pentoxifylline without plasticizer
2. Release from polymeric film plasticized with dibutyl sebacate
As a resuit of previous dissolution study data, dibutyl sebacate (DBS)
was added to the film formulation at different levels, 70%, 20%, and 30%,
and drug loading levels of 10%, 20%, and 60 ¾. The dissolution studies
show that there was no sign of film cracking at any level of plasticizer. Figure
6 shows that, at a 10% drug loading, as the DBS level increases, the release
rate increases due to a decrease in crystallinity of the polymer, which resuits
in a higher diffusivity of the drug in the polymer.[57, 58]
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Figure 6: Percentage of drug released as function of tïme (hrs) for films
containing 10 % pentoxifylline and 10 %, 20 %, and 30 % DBS
Figure 7 shows that increasing the level of plasticizer for the 20% drug
loading increases the release rate. It also makes evïdent that the release rate
is much higher than at a 10% drug loading, which is probably due to a mixed
mode release mechanism of diffusion through polymer and porous diffusion
f rom channels created as solid drug particles dissolve.
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Figure Z: Percentage of drug released as function of time (hrs) for films
containing 20 % pentoxïfylline and 10 %, 20 %, and 30 % DES
Figure 8 shows that there is no effect of the DBS on the drug release at
60% drug loading because the release occurs exclusively through the pores
created trom the dissolution of drug particles. Generally, drug release at both
10% and 20% drug loading occurs f irst trom drug particles at the surface of
the film in contact with dissolution liquid, then through a network of
interconnected pores that were created as the drug particles dissolved.[57,
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Figure 8: Percentage of drug released as function of tïme (hrs) for films
containing 60 % pentoxifylline and 10 % and 30 % DBS
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Figure 9: Percentage of drug released as function of tïme (hrs) for films
containing 10 %, 20 %, and 60 % of pentoxifyNine at a constant DBS
level of 10%
Figure 9 shows that the drug release from films at low levels (10%) of
DBS plasticizer is highly dependent on drug loading (10%, 20%, and 60 %).
As indicated by the slope of the curves, as the drug loading level increases,
there is a marked increase in the drug rate from the film.
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Figure 10: Percentage of drug released as function of tïme (hrs) for films
containing 10 %, 20 %, and 60 % of pentoxifylline at a constant DBS
level of 30 %( part-a)
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Figure 11: Percentage of drug released as function of time (hrs) for
films containing 10 %, 20 %, and 60 % of pentoxïfylline at a constant
DBS level of 30 %f part-b)
Agures 9, 10 and 11 and Tables 6 and 7 show the eftect of plasticizer
levels on the release kinetic. For 10% and 20% drug loading, as the
plasticizer levels (DES) increase, the release rate increases. This is
attributed to the decreasing crystallinity of the polymer, which results in a
higher diffusivity of the drug in the polymer. For 60% drug loading, an inverse
effect of the plasticizer (DES) level on drug release kinetics is observed; due
to the excess amount of plasticizer, which makes the drug particles and the
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micro-environment for diffusion extremely hydrophobic, the drug release rate
decreases as the plasticizer level increases. [45]
Drug loading Plastïcizer level T60%
(w!v) (vlv)
60% 10% 0.25 hour
20% 10% 45.00 hours
1 0% 10% 140.00 hours
Table 6: The effect of drug loading at constant plasticizer (10% DBS) on the
release kinetics, T60%.
Drug loading Plasticizer level
(wlv) (vlv)
60% 30% 2.58 hours
20% 30% 17.66 hours
10% 30% 32.50 hours
Table 7: The effect of drug loading at constant plasticizer (30% DBS) on the
kinetics release, T$0%.
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C. Characterization of the film
1. Differential scanning calorïmetry
Molecular weight Melting point Tg Recrystallization
c temperature
C
Low mol. Wt 137.70 48.00
64847
Low moLwtlDCM 144.65 50.00 101
High mol.wt 175.55 66.00
252073
High mol. 170.60 60.00 102
WtIDCM
Low & high 165.40 56.00
mol.wtIDCM
Low & high 158.00 26.00 58
mot.wt
IDCM/DBS
Table 8: The effect of resïdual solvent on m.p. and Tg of PLA with and
without plasticizer.
DSC was used to evaluate the effect of the solvent, dichioromethane
(DCM), on the polymer after spraying and evaporation. Ihe resuits, shown in
Table 8, demonstrate that DCM has no signiticant effect on the Tg and
melting point of PLA at low molecular weights of PLA. At a high molecular
weight of PLA, the 1g and melting point are signiticantly decreased. The
mixture of high and 10w molecular weight has a melting point around 165.40
C° and a 1g of 54.00 C° to 56.00 00. After adding DBS, the melting point and
the Tg are decreased. Based on previous work, the PLA has a Tg between
49.00 00 and 52.00 C° for a PLA with a molecular weight between 24.000
and 110.000 and a melting point of 1 72.00 00, which agrees with the resuits
that have been obtained tram the DSC work130, 59]
5$
gThe DSC scans of Figure 13 and 14 show the decrease in Tg and
the melting point of the mixture of 10W molecular weight and high
molecular weight of PLA after adding DBS.
Figure 12: DSC scan of a mîxture of 10w- and high-molecular-weïght
PLA dîssolved in the solvent dichloromethane (DCM) without DBS
after a second run showing the Tg
À
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Figure 13: Second run of a mixture of Iow- and high-molecular-weight
wïth plastïcîzer DBS dissolved ïn the solvent dichioromethane (DCM).
Table 9 and Figures 15 to 18 show the DSC results of different drug
loadings with different levels of DBS of PLA film. There is no peak for
pentoxifylline at 10% loading, which indicates the absence of crystalline drug
and suggests that the drug is molecularly dispersed in PLA. As Figure 13
shows, when the DSC scan was carried out for the same amount of drug
theoretically contained in the film at 10% drug loading, the drug peak could
easily be seen.
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Drug Drug DBS% m.p. Tg Pentoxifylline DBS
loading weight peak peak
% mg
10 0.8 10 1 59.40 50.00
—
—
154.30 26.00
20 1.3 10 1st15330 42.00 Small peak
—
2’ 147.50 27.00
60 8.2 10 141.20 -3.50 Peak
—
135.60
20 1.7 20 143.60 10.00 SmaIl peak Peak
10 0.9 30 146.90
— Peak
20 1.5 30 145.30
— SmaII Peak
141.50
60 8.9 30 138.20
— Peak peak
132.60
Table 9: DSC data of films with different pentoxifylline loadings and
dïfferent DBS levels
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Figure 14: DSC scan of pure drug (pentoxifylline) at a theoretical 10%
drug loading level
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At 20% and 60% loading, Figures 16 and 17 show that the intensity of
the pentoxitylline peaks is proportional to the quantity of drug in the film. The
Tg 26.00 C° ïs only detected at a level of 10% DES for the 10% and 20%
drug loading, while no Tg peak is detected at 60% drug loading. At 20% and
30% DES, the Tg is flot detected, whatever the drug loading. The DSC
shows that the melting point decreases as drug loading and DES levels
increase.
E
Figure 15: DSC scans of 60% pentoxifylline and 30% DBS after the first
run showïng pentoxifylline peak.
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Figure 16: DSC scan of 20% pentoxifylline and 30% DBS after the first run
showing a pentoxifylline peak.
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Fîgure 17: DSC scans of 10% Pentoxïfyllïne and 30% DBS after the first
run showing a plasticizer peak and the absent of the drug
(pentoxifylline) peak.
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2. Scanning-electron mïcroscopy
As is shown in Figures 19, 20, and 21, in scanning-electron microscopy
for the films before dissolution at tow drug loading level 10%, it appears that
drug parlicles on the surface of the film explain the initial burst that is
observed in dissolution studies.
Fïgure 18: SEM photo of 10% pentoxifylline and 10% DES film before
dissolution showing drug crystals on the film surface.
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At 20% drug Ioadings, a greater amount of drug particles on the surface
can be seen. At higher drug loading levels, 60%, the drug particles seem to
cover the surface of the film, which explains the very high release rate.
Figure 19: SEM photo of 20% pentoxifylline and 10% DBS film before
dissolution showing more drug crystals on the fîlm surface.
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Figure 20: SEM photo of 60% pentoxifylline film before dissolution,
showïng drug crystals covering the film surface
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On the other hand, Figures 22 and 23, photos for films after dissolution,
show surface pores within the film increase as drug loading levels increase.
Figure 21 at 60% loading demonstrates a greater pote density and more
homogeneous distribution of pores across the surface, where Figure 20 at
20% loading shows areas where there seems to be no potes. Close
evaluation of the pore structure in Figure 21 shows that there are pores
within the major pores.
Figure 21: SEM photo of 20% pentoxîfylline and 10% DBS film after 48
hours dissolution, showïng pores after pentoxifylline particles were
dissolved
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Figure 22: SEM photo of 60% pentoxifylline film after 3 hours
dissolution, showing the pores after the dissolution of the pentoxifylline
particles.
6$
Figure 24 shows a photomicrograph of a cross section of a film with a 60
% drug loadings atter 3 hours dissolution, which demonstrates a very
extensive porous network extending trom the surface. This suggests a
significant internai pore structure that wouid exptain the much higher release
rate of the 60% loading.
•1
I
Figure 23 : SEM photo of freeze fracture of 60% pentoxifylline film after
3 hours dissolution, showing the pores after the dissolution of the
pentoxïfylline partïcles.
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IV. Conclusion
This study. aimed to evaluate the release kïnetics of the drug model
(pentoxifylline) from a polymeric matrix containing 50% 10w molecular weight
PLA and 50% high molecular weight PLA. Other parameters, such as drug
loading levels and plasticizer levels, were also evaluated. Adding plasticizer
to the film formulation improves the physical properties of the film and
increases the release rate. Ihe drug release rate for 10% and 20% drug
loading from the polymeric matrix increases as the plasticizer level increases,
due to the decrease in the crystallinity of the polymer, as evidenced by the
decreasing 1g. This resuits in higher diffusivity of the drug in the polymer. At
low drug loading (10% and 20%), the release rate can be controlled by
adjusting the plasticizer level. At 60% drug loading, the release rate
decreases as the plasticizer level increases, due to the excess amount of
plasticizer that makes the drug particles and matrix more hydrophobic and
more slowly soluble. Ihe release rate of the drug from the film increases as
drug loading increases. Although not studied here, increasing the surface
area of the film is another parameter that can be used to control the release
rate of the drug trom the polymeric film.
The Difterential Scanning Calorimeter (DSC) shows that high and low
molecular weight PLAs have different Tg values. 1g values for the mixture of
high and low molecular weights of PLA decreases as plasticizer is added.
The Tg value can only be detected at 10% and 20% drug loadings and 10 ¾
plasticizer, which indicates significant residual crystallinity. Differential
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Scanning Calorimeter (DSC) scans of the film at 10% drug loading show no
detectable drug peak, while a DSC scan of the film at 10% drug loading can
detect the same amount of drug, thus indicating that most of the drug is
solubilized in the polymer/plasticizer matrix at this loading level.
Scanning electronic microscopy (SEM) photomicrographs before the
dissolution of the films with different drug loading levels shows the presence
of drug particles at the surface, even at the 10% loading. This is confirmed by
X-ray diffraction analysis. The presence of drug particles increases as the
drug loading levels increase. Scanning electronic microscope (SEM)
micrographs of films with increasing drug loadings after dissolution shows an
increasing porosity, which explains the increasing release rates with
increasing loading.
This work has demonstrated that plasticizer and drug loading levels can
be used to control drug release rate. The plasticizer has an unexpected
effect on the drug release rate. First, as expected, increasing the plasticizer
at 10w drug loading levels (10% and 20%) decreases the Tg of the polymeric
film, which results in an increased drug release rate for a fixed drug loading
level. Second, at a high drug loading level (60%), the plasticizer has an
inverse effect on the drug release rate, whereby the release rate decreases
as the plasticizer level increases. Since the drug release rate is dependent
on drug loading and the plasticizer level, different drug release rates can be
obtained by controlling these parameters.
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